[ARDX] Ardelyx, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 14.6 Change: 1.2 (8.96%)
Ext. hours: Change: 0 (0%)

chart ARDX

Refresh chart

Strongest Trends Summary For ARDX

ARDX is in the long-term down -91% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Ardelyx, Inc. discovers, develops, and commercializes non-systemic small molecule therapeutics for the gastrointestinal tract to treat cardio-renal and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal and metabolic diseases. It has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was founded in 2007 an

Fundamental Ratios
Shares Outstanding EPS-2.73 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -35.61% Sales Growth - Q/Q-7.19% P/E-1.59
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-3.46% ROE-6.28% ROI
Current Ratio5.12 Quick Ratio Long Term Debt/Equity Debt Ratio0.34
Gross Margin Operating Margin-15.85% Net Profit Margin-12.59% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities-1.05 M Cash From Operating Activities-8.21 M Gross Profit
Net Profit-3.5 M Operating Profit-3.49 M Total Assets105.4 M Total Current Assets101.91 M
Total Current Liabilities19.91 M Total Debt Total Liabilities47.4 M Total Revenue5.88 M
Technical Data
High 52 week7.9 Low 52 week1.66 Last close2.23 Last change-4.29%
RSI69.29 Average true range0.19 Beta1.5 Volume61.04 K
Simple moving average 20 days10.4% Simple moving average 50 days-8.8% Simple moving average 200 days-41.66%
Performance Data
Performance Week-7.08% Performance Month3.72% Performance Quart-39.89% Performance Half-52.04%
Performance Year-68.59% Performance Year-to-date24.58% Volatility daily5.5% Volatility weekly12.3%
Volatility monthly25.21% Volatility yearly87.35% Relative Volume187.64% Average Volume352.07 K
New High New Low


2020-05-26 09:00:00 | Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference

2020-05-21 17:23:00 | Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-05-18 16:01:00 | Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer

2020-05-12 10:44:02 | Will Ardelyx Continue to Surge Higher?

2020-05-11 12:00:04 | Ardelyx ARDX Upgraded to Strong Buy: Here's Why

2020-05-10 08:16:36 | Analysts Are Upgrading Ardelyx, Inc. NASDAQ:ARDX After Its Latest Results

2020-05-07 16:02:00 | Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights

2020-04-28 12:00:04 | Here's Why Momentum Investors Will Love Ardelyx ARDX

2020-04-23 06:14:29 | What Did Ardelyx, Inc.'s NASDAQ:ARDX CEO Take Home Last Year?

2020-04-17 07:30:10 | Knight Therapeutics Announces Approval of IBSRELA™ in Canada

2020-03-16 09:00:00 | Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

2020-03-09 08:15:33 | Rock star Growth Puts Ardelyx NASDAQ:ARDX In A Position To Use Debt

2020-03-06 17:15:10 | Ardelyx ARDX Reports Q4 Loss, Tops Revenue Estimates

2020-03-06 16:02:00 | Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

2020-02-26 12:30:05 | Ardelyx ARDX May Report Negative Earnings: Know the Trend Ahead of Q4 Release

2020-02-26 08:00:00 | Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference

2020-02-19 08:00:00 | Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference

2019-12-31 05:16:40 | How Ardelyx, Inc. NASDAQ:ARDX Can Impact Your Portfolio Volatility

2019-12-05 07:14:16 | The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

2019-12-04 23:32:00 | Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

2019-12-04 16:56:00 | Ardelyx Announces Proposed Public Offering of Common Stock

2019-12-04 07:06:30 | The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

2019-12-03 08:18:24 | UPDATE 2-Ardelyx drug reduces elevated phosphate levels, late-stage study shows

2019-12-03 07:25:00 | Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

2019-12-02 16:01:00 | Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

2019-11-27 07:26:05 | The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

2019-11-26 16:00:00 | Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference

2019-11-26 08:06:41 | The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

2019-11-25 18:00:00 | Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements

2019-11-06 16:05:00 | Ardelyx Announces Presentation at Kidney Week 2019

2019-11-06 16:02:00 | Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights

2019-11-01 06:13:54 | Why Ardelyx, Inc.'s NASDAQ:ARDX CEO Pay Matters To You

2019-10-10 16:00:00 | Ardelyx to Host Analyst Day in New York

2019-09-26 08:20:01 | Some Ardelyx NASDAQ:ARDX Shareholders Have Taken A Painful 73% Share Price Drop

2019-09-19 14:31:06 | Ironwood Amends Linzess Agreement with AstraZeneca in China

2019-09-17 16:01:00 | Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference

2019-09-13 12:29:27 | A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019

2019-09-13 11:08:03 | Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

2019-09-13 08:24:12 | Ardelyx ARDX in Focus: Stock Moves 8.3% Higher

2019-09-13 07:40:02 | The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

2019-09-12 15:12:00 | Ardelyx Receives FDA Approval for IBSRELA® Tenapanor, an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

2019-09-12 07:38:39 | The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study

2019-09-11 17:47:02 | East Bay company eyes first drug approval after decade-long journey

2019-09-04 16:42:04 | Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day

2019-09-04 12:07:41 | A Look At Benzinga Pro's Most-Searched Tickers For September 4, 2019

2019-09-04 12:00:00 | Why Ardelyx Shares Are Sinking Today

2019-09-04 10:31:02 | Ardelyx ARDX Gains on Tenapanor's Success in Pivotal Study

2019-09-04 10:02:02 | Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

2019-09-04 07:08:03 | The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

2019-09-03 10:56:00 | Why Ardelyx Is Soaring Today